<DOC>
	<DOCNO>NCT00084864</DOCNO>
	<brief_summary>RATIONALE : Calcitriol dexamethasone may slow growth prostate cancer cell . PURPOSE : This randomized phase II trial study well give calcitriol together dexamethasone radical prostatectomy work treat patient localize stage II stage III adenocarcinoma ( cancer ) prostate .</brief_summary>
	<brief_title>Calcitriol Dexamethasone Before Radical Prostatectomy Treating Patients With Localized Adenocarcinoma ( Cancer ) Prostate</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect calcitriol dexamethasone radical prostatectomy tumor vessel density patient localize adenocarcinoma prostate . - Determine effect regimen extent prostatic intraepithelial neoplasia patient . - Determine effect regimen expression apoptosis marker , p21 , p27 , prostate-specific antigen ( PSA ) , prostate-specific membrane antigen , VDR expression tumor-associated vascular endothelial cell endothelium derive normal-appearing prostate tumor patient . - Determine acute effect regimen serum PSA patient . - Determine toxicity regimen patient . OUTLINE : This two-stage , randomize , pilot study . - Stage 1 : Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral dexamethasone daily day 1-4 oral calcitriol daily day 2-4 weekly 4 week surgery . Within 48 hour last dose , patient undergo radical prostatectomy . - Arm II : Patients receive study drug , undergo radical prostatectomy . - Stage 2 : If sufficient activity see dexamethasone calcitriol regimen stage 1 , study expand additional patient randomize 1 4 treatment arm . - Arm I : Patients receive dexamethasone calcitriol stage 1 , arm I . - Arm II : Patients receive oral dexamethasone daily day 1-4 . - Arm III : Patients receive oral calcitriol daily day 2-4 . - Arm IV : Patients undergo radical prostatectomy stage 1 , arm II . In arm I , II , III , patient undergo radical prostatectomy stage 1 , arm I . Patients follow 1 , 3 , 12 month . PROJECTED ACCRUAL : A total 20-80 patient ( 20 stage 1 [ 10 per treatment arm ] 60 stage 2 ) accrue study within 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Organconfined disease cT1 , cT2 , cT3 tumor Patients cT1 tumor eligible ≥ 1 core biopsy ≥ 50 % tumor OR 50 % core examine contain tumor No small cell carcinoma prostate Scheduled radical prostatectomy PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Platelet count ≥ 100,000/mm^3 WBC ≥ 3,500/mm^3 Hepatic ALT AST ≤ 4 time normal Bilirubin ≤ 2 mg/dL Renal Creatinine ≤ 2 time upper limit normal Calcium ≤ 10.5 mg/dL No detectable renal stone CT scan ultrasound Other No history diabetes mellitus require pharmacotherapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy More 5 year since prior antiestrogens , antiandrogens , luteinizing hormonereleasing hormone agonist , estrogen , progestational agent Radiotherapy Not specify Surgery See Disease Characteristics No prior nephrectomy No prior prostatic surgery No prior cryotherapy transurethral resection prostate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>